ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0536

The EIF4 Translational Inhibitor Pateamine a Improves Immunological and Neurological Functions in BXSB.yaa Lupus Mice

Gonzalo Gómez-Hernández1, Nieves Varela1, Harini Bagavant2, Guillermo Barturen1, Marta E. Alarcon-Riquelme1 and Maria Morell1, 1GENYO.Center for Genomics and Oncological Research, Granada, Spain, 2Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: ACR Convergence 2021

Keywords: Animal Model, autoimmune diseases, neuropsychiatric disorders, Systemic lupus erythematosus (SLE), Therapy, alternative

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Title: SLE – Animal Models Poster (0534–0540)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance and activation of the immune response. Clinical manifestations are heterogeneous and several organs can be affected including skin, joints, central nervous system and kidney. Traditional treatments include the use of hydroxychloroquine, glucocorticosteroids, immunosuppressive and more recently, biological drugs such as belimumab or rituximab. In the last decade new alternatives have been proposed based on targeting interferon and cytokines. Mouse models have been extremely helpful to test the efficacy of new SLE therapies. In this work we analyze the therapeutic potential of a natural compound, Patemina A (PatA) to treat SLE. Pat A is an inhibitor of the translation initiation process with immunosuppressive properties that has been tested successfully in cancer mouse models.

Methods: To test Pat A efficiency in SLE we used the BXSB.Yaa lupus model. Animals were treated for 8 weeks starting at the initial stages of disease (12 weeks). Sera was collected every three weeks and disease signs were followed. At the final point we performed serological analyses (cytokines and autoantibodies), flow cytometry on spleen to evaluate different cell populations, kidney histological and functional assays and behavioral tests to evaluate neuropsychiatric changes.

Results: Our data shows that Pat A treatment increases the survival rate and is able to reduce circulating levels of proinflammatory cytokines and autoantibodies. We also observed improvement of cognitive functions (learning/memory, and depression behavioral tests) together with a reduction of proinflammatory cytokines locally in the hippocampus.

Conclusion: These data suggests that translation inhibition improves lupus disease signs at the immunological and neurological levels opening a new line of research based on translation inhibition to treat lupus and other autoimmune diseases.


Disclosures: G. Gómez-Hernández, None; N. Varela, None; H. Bagavant, None; G. Barturen, None; M. Alarcon-Riquelme, None; M. Morell, None.

To cite this abstract in AMA style:

Gómez-Hernández G, Varela N, Bagavant H, Barturen G, Alarcon-Riquelme M, Morell M. The EIF4 Translational Inhibitor Pateamine a Improves Immunological and Neurological Functions in BXSB.yaa Lupus Mice [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-eif4-translational-inhibitor-pateamine-a-improves-immunological-and-neurological-functions-in-bxsb-yaa-lupus-mice/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-eif4-translational-inhibitor-pateamine-a-improves-immunological-and-neurological-functions-in-bxsb-yaa-lupus-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology